Sensei Biotherapeutics (NASDAQ:FTH) Stock Falls 7% - What's Next?

Key Points

• Sensei Biotherapeutics shares fell 7% to approximately $21.63, with trading volume below the stock’s average daily level. The company’s market capitalization was about $560.6 million.
• Analyst sentiment remains favorable, with a consensus rating of “Moderate Buy” and an average price target of $56.25; individual targets ranged as high as $70.
• Sensei reported a quarterly loss of $2.84 per share, beating the consensus estimate of a $5.04 loss. Institutional investors own about 10.5% of the company, which is developing cancer immunotherapies including the lead program SNS-101.

Sensei Biotherapeutics, Inc. (NASDAQ:FTH - Get Free Report) shares were down 7% during trading on Tuesday. The company traded as low as $21.60 and last traded at $21.6310. Approximately 178,281 shares were traded during trading, a decline of 26% from the average daily volume of 240,852 shares. The stock had previously closed at $23.25.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Citizens Jmp started coverage on Sensei Biotherapeutics in a report on Monday, July 20th. They set an "outperform" rating and a $51.00 price objective on the stock. Raymond James Financial assumed coverage on Sensei Biotherapeutics in a report on Friday, July 31st. They issued an "outperform" rating and a $56.00 target price for the company. Oppenheimer began coverage on Sensei Biotherapeutics in a research report on Tuesday, July 28th. They set an "outperform" rating and a $60.00 target price for the company. TD Cowen started coverage on Sensei Biotherapeutics in a research report on Wednesday, September 9th. They set a "buy" rating for the company. Finally, Guggenheim initiated coverage on Sensei Biotherapeutics in a research note on Wednesday, September 16th. They issued a "buy" rating and a $70.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Sensei Biotherapeutics has an average rating of "Moderate Buy" and an average target price of $56.25.

Sensei Biotherapeutics Trading Down 6.7%

The company has a fifty day simple moving average of $31.75. The firm has a market cap of $560.60 million, a P/E ratio of -0.15 and a beta of -0.29.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, beating analysts' consensus estimates of ($5.04) by $2.20. As a group, sell-side analysts forecast that Sensei Biotherapeutics, Inc. will post -13.69 EPS for the current year.

Institutional Investors Weigh In On Sensei Biotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its position in shares of Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company's stock worth $1,041,000 after purchasing an additional 32,719 shares in the last quarter. Alyeska Investment Group L.P. acquired a new stake in shares of Sensei Biotherapeutics in the second quarter valued at approximately $3,610,000. Renaissance Technologies LLC increased its holdings in shares of Sensei Biotherapeutics by 178.2% in the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company's stock valued at $1,010,000 after purchasing an additional 20,525 shares in the last quarter. Stempoint Capital LP acquired a new stake in shares of Sensei Biotherapeutics in the first quarter valued at approximately $4,188,000. Finally, Vivo Capital LLC bought a new position in Sensei Biotherapeutics in the 1st quarter worth approximately $22,758,000. Institutional investors and hedge funds own 10.50% of the company's stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company's approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients' responses to existing cancer treatments.

Sensei's pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.